<DOC>
	<DOCNO>NCT00176059</DOCNO>
	<brief_summary>The aim randomize prospective study renal transplant recipient investigate immunological short long-term effect IVIG induction therapy . Furthermore clinical endpoint ( patient graft survival , incidence acute chronic rejection , infectious disease graft function ) three year posttransplant analyze .</brief_summary>
	<brief_title>Immunoregulatory Effects Immunoglobulin Induction Therapy Renal Transplant Recipients</brief_title>
	<detailed_description>Intravenous immunoglobulin ( IVIG ) preparation know effective treatment various autoimmune inflammatory disorder due immunomodulatory antiinflammatory property . It demonstrate IVIG effective treatment acute vascular rejection steroid resistant cellular rejection . Furthermore , IVIG use inhibit production lymphocytotoxic antibody highly sensitized patient successful cadaveric living renal transplantation could perform . The aim randomize prospective study renal transplant recipient investigate immunological short long-term effect IVIG induction therapy Th1 , Th2 B-cell/monocyte response , expression adhesion molecule , costimulatory factor cytokine receptor secretion immunoregulatory autoantibody ( anti-F ( ab ) - , anti-F ( ab ' ) 2G- , anti-hinge autoantibody ) . These autoantibody show significantly affect risk chronic rejection graft loss . Furthermore , clinical endpoint ( patient gaft survival , incidence acute chronic rejection , infectious disease graft function ) 3 year analyze .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Autoantibodies</mesh_term>
	<criteria>renal transplant recipient Giessen renal transplant unit cadaveric living renal transplant first retransplants Contraindications bloodtaking ( anaemia hemoglobin &lt; 9,5 g/l , hypotension ) intravenous immunoglobulin therapy last half year study entry Hyperimmunoglobulin therapy severe CMV infection Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>immunoglobulin , intravenous</keyword>
	<keyword>kidney transplantation</keyword>
	<keyword>acute rejection</keyword>
	<keyword>chronic rejection</keyword>
	<keyword>regulatory autoantibody</keyword>
	<keyword>Th1</keyword>
	<keyword>Th2</keyword>
	<keyword>B Cell</keyword>
	<keyword>Monokines</keyword>
	<keyword>Cytokine promoter gene polymorphism</keyword>
</DOC>